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Hormonal contraceptives are on the market for more than 50 years and used by 100
million women worldwide. However, while endogenous steroids have been convincingly
associated with change in brain structure, function and cognitive performance, the effects
of synthetic steroids contained in hormonal contraceptives on brain and cognition have
barely been investigated. In this article we summarize the sparse findings, describing
brain structural, functional and behavioral findings from the literature and suggest that
synthetic steroids may contribute to masculinizing as well as feminizing effects on brain
and behavior. We try to identify methodological challenges, explain, how results on
endogenous steroids may transfer into research on hormonal contraceptives and point
out factors that need to be controlled in the study of hormonal contraceptive dependent
effects. We conclude that there is a strong need for more systematic studies, especially on
brain structural, functional and cognitive changes due to hormonal contraceptive use. The
hormonal contraceptive pill is the major tool for population control. Hence, such behavioral
changes could cause a shift in society dynamics and should not stay unattended.
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INTRODUCTION
Hormonal contraceptive pills are on the market for more than
50 years (see Box 1). Today, about 100 million women world-
wide use combined oral contraceptives (Petitti, 2003). However,
despite the well characterized impact of endogenous female sex
hormones on structure and physiology of the brain and their
impact on cognition and mood, very little is known about the
impact of synthetic steroids on cognitive abilities, brain struc-
ture and function. The impact of hormonal contraceptives on
the brain is of great importance equally to the private user and
physicians as well as to clinical and basic research. The far reach-
ing consequences of hormonal contraceptives are illustrated by a
few contrasting facts. (i) Kinsley and Meyer notice that the intake
of steroids by an athlete is considered as abuse and “doping”
by androgens is strongly sanctioned by society. On the contrary
the intake of steroids in women is recommended for birth con-
trol around the world (http://www.scientificamerican.com). (ii)
Adolescent girls start taking hormonal contraceptives earlier and
earlier, often shortly after onset of puberty (Parkes et al., 2009).
However, the majority of research on steroid actions in the brain
focuses on post-menopausal hormone replacement therapy. (iii)
Traditionally, medical as well as psychological research focused
on male participants, because hormone fluctuations throughout
the menstrual cycle were suspected to affect the results—rightly,
as it turned out. Nowadays, numerous women participate in
scientific studies. However, while participants on medication
are excluded, studies hardly control for the use of hormonal
contraception.
In this article we summarize the sparse findings indicat-
ing brain structural, functional and behavioral changes due
to hormonal contraceptive use and try to give methodologi-
cal impulses for future research. The interpretation of these
changes are demanding and at themoment speculative. Although,
endogenous female sex hormones have been convincingly associ-
ated with changes in brain structure and physiology—estradiol
and progesterone modulate e.g., glutamatergic, GABAergic, sero-
tonergic and dopaminergic transmission (see Sacher et al., this
topic)—the neuronal targets of synthetic steroids are almost
unknown. Changes in brain structure and chemistry cause
changes in cognition, emotion and personality and consequently
in observable behaviors. If a majority of women use hormonal
contraception, such behavioral changes could cause a shift in
society dynamics. Since the pill is the major tool for pop-
ulation control, it is time to find out what it does to our
brain.
EFFECTS OF HORMONAL CONTRACEPTIVES: “FEMINIZING”
OR “MASCULINIZING”?
The combined oral contraceptive pill (OC) typically contains
0.02–0.04mg ethinylestradiol and varying levels of synthetic pro-
gestins, which can be classified by their generation. Progestins
are a heterogenous class of synthetic steroids, which differ in
their strength of binding to steroid receptors, the sex hormone
binding globuline or to enzymes involved in the metabolism
of endogenous steroids (e.g., Sitruk-Ware, 2006). Furthermore,
they differ in their impact on blood glucose levels and the
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Box 1 | A short history of hormonal contraception.
Within about a century, physicians, biologists, and chemists around the world elucidated the physiology of the ovary, manipulated its
function, and triggered a global experiment, which influenced our society. At the end of the 19th century, anatomists concluded from
histological sections that the corpus luteum in the ovary is a gland secreting a factor into the blood relevant to pregnancy (Frobenius and
Fraenkel, 1999). In the early 1920s, the Austrian physician, Ludwig Haberlandt (1885–1932), published his findings on temporary sterilization
of the female body. He realized that transplantation of ovaries from pregnant to non-pregnant animals prohibits pregnancy in the receiver. In
a translational approach, Haberlandt suggested hormonal contraception also in women and collaborated with the company of G. Richter in
Budapest (Hungary) to develop contraceptives for women (Haberlandt, 2009). In 1923, Edgar Allen and Edward Adelbert Doisy (1893–1986)
published a bioassay, which used the vaginal epithelium response in castrated rodents to identify the bioactive component among corpus
luteum factors as well as other sex hormones (Frobenius and Fraenkel, 1999). In the 1930s, progesterone was isolated from glandular
extracts independently by four research groups, and its chemical structure was characterized by the chemist Karl Heinrich Slotta (1895–
1987) (Frobenius and Fraenkel, 1999; Hawgood, 2001). In 1944, the Germans, Bickenbach und Paulikovics, published that progesterone
(20mg, daily) suppresses ovulation in women (Ludwig, 2011). Because progesterone is metabolized during the entero-hepatical passage,
synthesis of chemically modified gestagens was a major challenge. Carl Djerassi, an Austrian-American chemist (born in Vienna in 1923),
synthesized norethindrone, the first oral contraceptive, in the early 1950s. In the late 1950s, the American biologist, Gregory Goodwin
Pincus (1903–1967) proved in a large scale study that oral application of hormonal contraceptives prevents pregnancy in women. In 1960,
the “Food and Drug Administration” in the USA legalized the first contraceptive (Enovid®), a combination pill containing 10mg of the
progestogen, norethynodrel, and 150μg of the estrogen, mestranol. In 1961, the pill (Anovlar®, Bayer Schering Pharma AG) was legalized
in Europe. The minipil, a progestine-only pill, was introduced into the market in the 1960s.
lipid profile (e.g., Sitruk-Ware, 2006). Importantly, older gen-
eration progestins (e.g., Levonorgestrel, desogestel, gestoden,
norgestimat), are as derivates of 19-nortestosterone, a common
anabolic steroid (Brueggemeier, 2006), able to activate andro-
gen receptors and exert androgenic actions (Sitruk-Ware, 2006;
Wiegratz and Kuhl, 2006). Newer progestins (e.g., dienogest,
drospirenone) on the other hand, bind very specifically to the pro-
gesterone receptor and are anti-androgenic (Wiegratz and Kuhl,
2006).
In the following we describe several mechanisms that may
explain the effects of synthetic steroids on brain and behavior.
We refer to an effect as “feminizing,” if it enhances a structural
or functional sexual dimorphism favoring women. We refer to an
effect as “masculinizing,” if it reduces a structural or functional
sexual dimorphism favoring men.
SYNTHETIC STEROIDS—POSSIBLE MECHANISMS OF ACTION
Since ethinylestradiol and synthetic progestins act on estrogen
and progesterone receptors and OC reduce endogenous testos-
terone levels (e.g., Jung-Hoffman and Kuhl, 1987; Graham et al.,
2007; Hietala et al., 2007), any hormonal contraceptive, irrespec-
tive of the progestin component, may show feminizing effects on
brain and behavior.
However, hormonal contraceptives do also lead to a reduction
of endogenous estradiol and progesterone levels (e.g., Sahlberg
et al., 1987). In the presence of high levels of progesterone,
testosterone-actions are impaired, because progesterone has a
high affinity for the enzyme 5α-reductase, which is respon-
sible for the conversion of testosterone into the physiolog-
ically more active dihydrotestosterone (Wright et al., 1983).
If progesterone levels are reduced, more testosterone can be
converted to dihydrotestosterone. Thus, any hormonal contra-
ceptives, irrespective of the progestin component, may facili-
tate testosterone actions on the brain, thereby masculinizing
brain structure, function and behavior. Alternatively, it has been
argued that some masculinizing effects are promoted by estro-
gen receptors after testosterone has been locally converted to
estrogen via the enzyme aromatase (Roselli, 2007). Consequently,
estrogenic actions of ethinylestradiol may contribute to pos-
sible masculinizing effects of hormonal contraceptives on the
brain.
ANDROGENIC vs. ANTI-ANDROGENIC PROGESTINS
Furthermore, the actions of synthetic progestins on the andro-
gen receptors, may contribute to possible masculinizing and
feminizing effects. While androgenic progestins may promote
masculinizing effects, anti-androgenic progestins may promote
feminizing effects. This distinction has important methodologi-
cal consequences. The preferable approach to studying the effect
of hormonal contraceptives in brain and behavior is a within-
subjects design, i.e., comparing women to themselves, before,
during and after the period of contraceptive use. Since this
is however complicated, costly and time-consuming, hormonal
contraceptive dependent effects are often studied by comparing
a group of OC users to a group of non-users. If the group of OC
users is heterogenous with respect to the androgenicity of the pro-
gestin component, possible feminizing and masculinizing effects
may counteract each other, leading to results that either under- or
over-estimate the actual effects and are hard to compare between
different studies. While the first studies in this domain added
important explorative impulses, by demonstrating that OCs may
indeed influence brain and behavior, we strongly argue that the
androgenicity of the progestin component is an important factor
that should be controlled in future studies. An interesting obser-
vation from our own research experience in that respect may help
when comparing findings between studies. We conducted two
studies on the effects of OCs only about a year and a half apart,
the first one in middle Europe (Austria; Pletzer et al., 2014a), the
second one in the US (California, Pletzer et al., 2014b). While
in the Austrian sample (Pletzer et al., 2014a), the group of OC
users consisted of a majority of women using newer pills contain-
ing anti-androgenic progestins, in the US sample (Pletzer et al.,
2014b), all OC users were on older pills containing androgenic
progestins.
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EFFECTS OF HORMONAL CONTRACEPTIVES ON BRAIN STRUCTURE
Adult brain structure is not static, but subject to dynamic changes
with age. These changes do differentially affect different brain
areas, i.e., gray matter volumes in some areas decline more
strongly with age than others. A strong age-related decline has
for example been demonstrated in the prefrontal cortex, as well
as the hippocampus (e.g., Sowell et al., 2003).
Recent results demonstrated that regional gray matter volumes
in the prefrontal cortex, as well as the anterior cingulate gyrus
are larger in mixed samples of androgenic and anti-androgenic
OC users compared to non-users (Pletzer et al., 2010; DeBondt
et al., 2013). These regions are already larger in women compared
to men (e.g., Good et al., 2001; Pletzer et al., 2010). However,
regional gray matter volumes of OC-users were also larger in
the cerebellum, hippocampi, parahippocampal and fusiform gyri
(Pletzer et al., 2010; DeBondt et al., 2013). Those regions are on
the average larger in men compared to women (e.g., Good et al.,
2001; Pletzer et al., 2010). Results from rodent hippocampi sug-
gest that these volume increases may be attributed to an increase
in synaptic spine density mediated by estrogen receptors (e.g.,
Murphy et al., 1998; McEwen, 2002; Smith et al., 2009), but an
increase in astrocyte volume in response to estradiol has also been
suggested (e.g., Spencer et al., 2008).
Newer results from our own lab, suggest that the effects in cere-
bellum, parahippocampus and fusiform gyri are attributable to
OCs containing anti-androgenic progestins, while the results in
the prefrontal cortex are to be interpreted with care (Pletzer et al.,
submitted). We demonstrate that some structural effects increase
with the duration of pill use, some interact with the age of the par-
ticipants and some may not be completely reversible, and hence
the duration of previous pill use in the group of non-users plays
an important role. Thus, despite the androgenicity of progestins,
the duration of (previous) pill use and age are important fac-
tors, that should be controlled when studying the effects of OCs
on brain and behavior. OCs, in particular those containing anti-
androgenic progestins, are commonly used by younger women,
while naturally cycling women tend to be on average a few years
older.
EFFECTS OF HORMONAL CONTRACEPTIVES ON BRAIN
FUNCTION—NEUROCOGNITIVE FINDINGS
Synthetic steroids may however, not only cause a structural re-
organization of the brain, but—even more importantly—induce
changes in neurochemistry and brain function, which are cur-
rently relatively unexplored. Despite the relatively robust finding
that OC users show altered mate preferences (e.g., Alvergne and
Lummaa, 2009), accompanied by changes in brain activation
patterns during viewing of erotic stimuli (Abler et al., 2013),
OC dependent changes in cognitive performance have not been
studied systematically.
Scattered over several countries and decades, it has been
reported that OC users show enhanced verbal memory (Mordecai
et al., 2008), recognition working memory during sleep depri-
vation (Wright and Badia, 1999), a lack of memory impair-
ment due to cortisol (Kuhlmann and Wolf, 2005) and better
dream recall (Sheldrake and Cormack, 1976) compared to non-
users. These verbal abilities and memory are usually thought to
favor women (e.g., Andreano and Cahill, 2009). However, non-
significant effects were reported for other measures of verbal
abilities, like verbal fluency (Mordecai et al., 2008) or a verbose-
quential task (Gordon and Lee, 1993), while verbal reaction times
were slower in OC users compared to non-users in an older
study (Garrett and Elder, 1984). First evidence for brain func-
tional differences between OC users and non-users has also been
reported in the verbal domain. A German brain imaging study
(Rumberg et al., 2010) observed that during a word generation
task OC users showed stronger activations in right-hemispheric
task-specific areas than non-users. This is of particular interest,
since the peak coordinates of the task-specific activations were
left-lateralized in all participants and sex differences in lateraliza-
tion have long been discussed in particular with respect to verbal
tasks (e.g., Renteria, 2012).
On the other hand, some studies report better mental rotation
performance in OC users compared to non-users (Wright and
Badia, 1999; Wharton et al., 2008), although other studies report
non-significant effects on visuospatial tasks (Gordon and Lee,
1993; Mordecai et al., 2008). Spatial abilities have robustly been
observed to favor men (Andreano and Cahill, 2009). Wharton
et al. (2008) nicely demonstrated that mental rotation perfor-
mance does not only correlate with hormonal contraceptive use,
but also with the androgenicity of the progestin component. Users
of drospirenone-containing contraceptives performed worse on
the mental rotation task than non-users. Neuroimaging studies
exploring functional differences in spatial tasks betweenOC-users
and non-users are still lacking. However, it has been demon-
strated that brain activation patterns are masculinized in numer-
ical tasks (Pletzer et al., 2014a), which have been related to spatial
abilities (e.g., Hubbard et al., 2005).
Furthermore, OC users perform like men in an emotional
memory paradigm, designed by Cahill and coworkers (Nielsen
et al., 2011, 2013) and in a Navon paradigm (Pletzer et al., 2014b),
both studies conducted on US samples. Brain functional differ-
ences between OC users and non-users have also been reported
during the resting state (Petersen et al., 2014), during face pro-
cessing (Mareckova et al., 2012) and during reward processing
(Bonenberger et al., 2013). However, further more systematic
studies are needed to reveal the true nature of OC-dependent
effects on cognition as well as the impact of synthetic steroids on
the neuronal correlates. Importantly, it has been demonstrated
that endogenous sex hormones, in particular estrogen, affect
cognitive performance differentially in different subpopulations
of women, as some neurotransmitters (e.g., dopamine) affect
behavior in an inverse U-shaped manner (Jacobs and D’Esposito,
2011; Colzato and Hommel, 2014). Hence, like in the study of
menstrual cycle dependent effects (Colzato and Hommel, 2014),
it might be worth considering neurotransmitter baseline levels,
when studying the effects of hormonal contraceptives on brain
and behavior.
EFFECTS OF HORMONAL CONTRACEPTIVES ON EMOTION
Reports on OC-related mood changes are inconsistent, rang-
ing from beneficial in most women (Oinonen and Mazmanian,
2002) to increased rates of depression, anxiety, fatigue, neu-
rotic symptoms, compulsion and anger (Robinson et al., 2004;
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Kulkarni, 2007). Repeated findings of beneficial mood changes
may however be biased by data sampling. Only women, who
continue the intake of oral contraceptives (“survivor effect”) are
included in those studies, while women, who discontinue the use
of oral contraceptives due to negative emotional side effects, do
not contribute to these results (Oinonen and Mazmanian, 2002).
Possible physiological mechanisms underlying both posi-
tive and negative mood swings in oral contraceptive users
are manifold and at the moment speculative. Elevated levels
of estradiol have anti-depressive effects (Moses-Kolko, 2009;
Estrada-Camarena, 2010), presumably due to its serotonin (5-
HT) enhancing property (e.g., Bethea et al., 2002). A decline in
estradiol at the end of the menstrual cycle, post-partum or in the
menopause has been associated with negative mood changes and
depressive symptoms during these phases (Moses-Kolko, 2009).
On the one hand combined OCs contain ethinyl-estradiol as
synthetic agonist for estradiol receptors, which could promote
positive mood changes. Antagonistic properties for the 5-HT3
receptor have been demonstrated not only for estradiol, but also
for ethinylestradiol (Wetzel et al., 1998). On the other hand the
levels of endogenous estradiol decline as a consequence of OCs
(e.g., Sahlberg et al., 1987), which could result in negative mood
changes. In female cynomolgus monkeys on OCs a decreased
prolactin response was observed, suggesting reduced serotonergic
activity (Henderson and Shively, 2004). Progesterone, however,
may promote positive mood changes at low concentrations and
negative mood changes at high concentrations due to bipha-
sic effects on GABAergic neurons (Andréen et al., 2009). Again,
synthetic progestins as contained in OCs simultaneously act as
progesterone receptor agonist and reduce the level of endoge-
nous progesterone (Wright et al., 1983; Sahlberg et al., 1987).
In a meta-analysis Oinonen and Mazmanian (2002) suggest that
the progesterone/estrogen ratio correlates to the direction of
emotional changes.
In summary, these results suggest that there are (at least)
two populations of women with differential emotional responses
to oral contraceptive use. Interestingly, the majority of studies
focused on depressive symptoms, while other emotional and per-
sonality dimensions, like aggression or empathy, have hardly been
investigated.
PUBERTY AND HORMONAL CONTRACEPTIVES
Progestin affecting either metabolism of neurosteroids or bind-
ing to GABAA receptors may have not only transient but also
neuroplastic consequences. We assume that the potential influ-
ence of progestins on GABAergic transmission is highly rele-
vant in pubescent girls using hormonal contraceptives. (1) With
onset of puberty, neurosteroid sensitive GABA receptor expres-
sion increases at extrasynaptic sites in female mice (Smith, 2009).
(2) Enhanced GABAergic transmission shortens whereas depres-
sion of GABAergic transmission extends the critical period in
structural consolidation of neuronal circuits in the visual cortex
in mice (Hensch, 2005). (3) Final volume of the prefrontal cortex
is not reached until the early twenties in humans (Yurgelun-
Todd, 2007). The maturing of the prefrontal cortex is associated
with improvement in cognitive abilities as well as behavioral con-
trol (Yurgelun-Todd, 2007). The prefrontal cortex appears to be
one target of structural changes in hormonal contraceptive users
(Pletzer et al., 2010; DeBondt et al., 2013). Accordingly, pharma-
cological intervention by the early use of hormonal contraceptives
could affect the differentiation of neural circuits in the prefrontal
cortex.
SUMMARY AND CONCLUSION
First and foremost, we conclude that there is a strong demand
for additional studies on how hormonal contraceptives affect the
brain from the molecular to the behavioral level. Thus, future
studies aiming to investigate “normal” brain functioning, should
control for the use of hormonal contraceptives among their
participants. At both the structural as well as behavioral level,
feminizing and masculinizing effects of hormonal contraceptives
have been observed simultaneously. However, these changes may
show differential manifestation at the behavioral level in differ-
ent subpopulations of women. As the number of women using
oral contraceptives constantly increases, while the age of first con-
traceptive use constantly decreases down to sensitive neuroplastic
periods during puberty, the associated changes in personality and
social behavior imply significant consequences for society.
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